Of four treatment response measures recorded at 6 months of mepolizumab treatment, an Asthma Control Questionnaire score was ...

GSK plc (LSE/NYSE: GSK) today announced that new drug applications have been accepted for review by the China National Medical Products Administration and submitted to the Japanese Ministry of Health, ...

An estimated 136 million asthma exacerbations occur globally each year, 10 million of those in the US. Physically threatening and emotionally significant for patients, such exacerbations can be fatal.

LONDON - GSK plc (LSE/NYSE: GSK) has announced the acceptance of regulatory filings in China and Japan for depemokimab, a new biologic treatment for asthma with type 2 inflammation and chronic ...

MUNICH, Germany I January 30, 2025 I Ethris GmbH, a leading biotechnology company pioneering next-generation RNA therapeutics and vaccines, today announced ...

The Nose Knows: Nasal Swab Detects Asthma Type in Kids Jan. 2, 2025 — A new, non-invasive nasal swab test for kids that diagnoses specific asthma subtype, or endotype, could help clinicians ...

and on the rate and severity of asthma exacerbations, as well as the potential modification of inflammatory mechanisms and varying efficacy in specific asthma phenotypes (such as smoking asthmatics).

GSK plc has announced that new drug applications have been accepted for review by the China National Medical Products ...

For many people suffering from asthma, the winter months and the colder air can trigger asthma symptoms and flare-ups, which ...

Depemokimab is a follow-up to GSK's Nucala (mepolizumab), a once-monthly IL-5 inhibitor approved for severe asthma, CRSwNP, ...

Your provider may offer you a number of possible treatments for GERD: Both medical and surgical treatments have been shown to decrease nighttime symptoms, decrease the frequency of asthma ...

Chronic obstructive pulmonary disease (COPD) is a manifestation of structural violence, the process through which societies ...